Switching On the Silent Gene in Rett Syndrome
August 25, 2025
Inhibiting miR106a restores expression of MECP2 and improves outcomes in mouse models of Rett syndrome.
2 min read
False
Advertisement
Cell & Gene
The Medicine Maker Presents Sharing is Caring: The Secrets of CGT
August 13, 2025
From standardizing CAR-T manufacturing to blockchain-backed data sharing, this roundtable tackles what it takes to scale life-saving advanced therapies.
1 min read
Innovation Awards
Future of Pharma
Technology & Manufacturing
Industry News
Cell & Gene
Bioprocessing
2025 Innovation Awards: Nominate Now
August 13, 2025
Nominations are now open for The Medicine Maker 2025 Innovation Awards celebrating drug development and manufacturing technologies.
2 min read
Political Upheaval Forces Medical Centers to Adapt
By Heather Purvis
August 12, 2025
Academic medical centers are racing to adapt as political turnover and funding uncertainty threaten the future of cell and gene therapy research.
5 min read
Allogene Amends Phase II Cell Therapy Trial After Patient Death
August 11, 2025
The trial will continue, but development activities associated with a monoclonal antibody are to be discontinued
2 min read
What Happened with Sarepta, Elevidys and Vinay Prasad?
By Stephanie Vine
August 4, 2025
FDA investigations, shipments holds, a resignation at the FDA and a negative opinion in Europe… I look into the recent controversy
5 min read
The Priorities for Cell and Gene in 2025 and 2026
July 25, 2025
Thirteen experts give their views – with improving patient access to these therapies being a key theme.
1 min read
Improving Immunotherapies With Digital Monitoring
July 24, 2025
An expert explains how digital technologies are helping to prevent cytokine release syndrome from immunotherapies.
6 min read
This Week’s CGT News: Partnership to Boost Australian CGT Landscape
By Rob Coker
July 24, 2025
Our latest news roundup reports on Elevidys, CGT Catapult funding, a new Australia-based partnership, and more.
4 min read
Eight Reflections on the Acquisition of Bluebird Bio
By Stephanie Vine
July 22, 2025
“The industry will recover.” Experts reflect on what the bluebird bio acquisition means for the advanced therapies sector and the lessons that have been learned.
4 min read
